ME03367B - Formulacija rnk za imunoterapiju - Google Patents

Formulacija rnk za imunoterapiju

Info

Publication number
ME03367B
ME03367B MEP-2019-90A MEP201990A ME03367B ME 03367 B ME03367 B ME 03367B ME P201990 A MEP201990 A ME P201990A ME 03367 B ME03367 B ME 03367B
Authority
ME
Montenegro
Prior art keywords
immunotherapy
rna formulation
rna
formulation
Prior art date
Application number
MEP-2019-90A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ugur Sahin
Heinrich Haas
Sebastian Kreiter
Mustafa Diken
Daniel Fritz
Martin Meng
Lena Mareen Kranz
Kerstin Reuter
Original Assignee
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/001319 external-priority patent/WO2013143555A1/en
Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Rna Pharmaceuticals Gmbh filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Publication of ME03367B publication Critical patent/ME03367B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MEP-2019-90A 2012-03-26 2013-03-25 Formulacija rnk za imunoterapiju ME03367B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/001319 WO2013143555A1 (en) 2012-03-26 2012-03-26 Rna formulation for immunotherapy
EP13713356.7A EP2830593B1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy
PCT/EP2013/000902 WO2013143683A1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy

Publications (1)

Publication Number Publication Date
ME03367B true ME03367B (me) 2019-10-20

Family

ID=52114006

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-90A ME03367B (me) 2012-03-26 2013-03-25 Formulacija rnk za imunoterapiju

Country Status (9)

Country Link
EP (3) EP3777840B1 (me)
CY (2) CY1121697T1 (me)
DK (1) DK3427723T3 (me)
HR (1) HRP20190607T1 (me)
ME (1) ME03367B (me)
PL (2) PL2830593T3 (me)
RS (1) RS58794B1 (me)
SI (1) SI2830593T1 (me)
SM (1) SMT201900302T1 (me)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
SG11202002579SA (en) * 2017-10-20 2020-05-28 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
CN113225313A (zh) * 2021-03-26 2021-08-06 大唐三门峡发电有限责任公司 一种用于dcs系统的信息安全防护系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
CA2766907A1 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
AU2011276234B2 (en) * 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
WO2013113325A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation

Also Published As

Publication number Publication date
DK3427723T3 (da) 2020-10-12
EP2830593B1 (en) 2019-02-27
PL2830593T3 (pl) 2019-08-30
SMT201900302T1 (it) 2019-07-11
EP2830593A1 (en) 2015-02-04
PL3427723T3 (pl) 2021-01-11
CY1121697T1 (el) 2020-07-31
CY1123453T1 (el) 2022-03-24
EP3777840B1 (en) 2025-04-23
EP3427723A1 (en) 2019-01-16
RS58794B1 (sr) 2019-07-31
HRP20190607T1 (hr) 2019-07-12
EP3777840A1 (en) 2021-02-17
SI2830593T1 (sl) 2019-07-31
EP3427723B1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
SMT202000603T1 (it) Formulazione di rna per immunoterapia
DK2922554T3 (en) Terminalt modificeret rna
IL236772A0 (en) Preparations for directed immunotherapy
PL3434695T3 (pl) Ulepszona immunoterapia
ZA201502880B (en) Compositions and methods for immunotherapy
PL2647387T3 (pl) Kompozycja szczepionki
GB201111438D0 (en) Formulation
ZA201309221B (en) Formulation
GB201506603D0 (en) Photobioreactor
ZA201402456B (en) Formulation
ME03367B (me) Formulacija rnk za imunoterapiju
GB201110278D0 (en) Formulations
GB201106958D0 (en) Formulation
PL2908857T3 (pl) Kompozycje do immunoterapii
GB201104284D0 (en) Formulation
GB201211247D0 (en) Improved formulation
GB201213825D0 (en) Damper-device for bouncing-device
PL398028A1 (pl) Fotobioreaktor
GB201206178D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201111013D0 (en) Formulations
GB201105360D0 (en) Formulations